Probiotics for IBS: Evidence-Based Strains That Actually Work
What peer-reviewed research says about which probiotic strains reduce abdominal pain, bloating, and bowel irregularity in irritable bowel syndrome
Irritable bowel syndrome (IBS) is one of the most common—and most frustrating—gastrointestinal conditions in the world. It affects an estimated 10–25% of adults in the United States alone, yet its underlying cause remains incompletely understood and no universal treatment exists.[1] For people living with the chronic abdominal pain, unpredictable bloating, and disrupted bowel habits that define IBS, that gap between prevalence and effective treatment is more than a statistic—it's daily life.
What has become increasingly clear from microbiome research is that gut dysbiosis—an imbalance in the composition and diversity of intestinal bacteria—plays a central role in IBS symptom generation.[2] This discovery has directed serious scientific attention toward probiotics as a therapeutic strategy: if disrupted gut bacteria contribute to IBS, restoring microbial balance may help resolve it. But not all probiotics are equally supported by evidence, and not all IBS symptoms respond to the same strains.
This article examines the peer-reviewed research on specific probiotic strains for IBS—focusing exclusively on those found in MicroBiome Restore—and what the clinical evidence actually says about their ability to address IBS symptoms.
Key Takeaways
- Gut dysbiosis is consistently documented in IBS patients, with reduced microbial diversity and altered bacterial composition compared to healthy controls—making probiotic therapy a scientifically rational approach.[2]
- Bacillus coagulans ranks first overall for IBS symptom improvement in a network meta-analysis of 43 randomized controlled trials covering 5,531 patients—outperforming all other probiotic species for global symptom relief, abdominal pain, and bloating.[3]
- Lactobacillus plantarum reduced abdominal pain frequency and bloating in a double-blind, placebo-controlled trial of 214 IBS patients meeting Rome III criteria, with 78.1% rating treatment efficacy as "good or excellent" vs. 8.1% for placebo.[4]
- Formulations based on L. rhamnosus and L. acidophilus achieved the highest efficacy scores in a PRISMA systematic review and multi-criteria analysis of 104 IBS clinical studies, particularly for quality of life, bloating, and abdominal pain.[5]
- Lactobacillus gasseri improved abdominal pain in IBS-D in a randomized, double-blind, placebo-controlled trial, with significant improvements in distension, daily life disruption, and bowel frequency.[6]
- Multi-strain probiotic formulas show more consistent benefit than single-strain products, with a systematic review finding beneficial effects more distinct in multi-strain trials of 8+ weeks.[7]
What Is IBS? Symptoms, Subtypes, and the Gut Connection
Irritable bowel syndrome is classified as a disorder of gut–brain interaction (DGBI), meaning it involves disrupted communication between the central nervous system and the enteric nervous system of the gastrointestinal tract. According to the Rome IV diagnostic criteria, IBS is defined by recurrent abdominal pain occurring at least one day per week in the last three months, associated with changes in stool frequency or form, and onset at least six months before diagnosis.[1]
Beyond pain, IBS commonly presents with bloating, gas, cramping, and a persistent sense of incomplete evacuation. The condition significantly reduces quality of life, drives substantial healthcare costs, and is frequently accompanied by psychological comorbidities including anxiety and depression. Importantly, IBS is not a single uniform disease—it presents across four recognized subtypes based on predominant bowel patterns.
Although conventional treatments address specific symptoms—antispasmodics for cramping, laxatives for IBS-C, antidiarrheal agents for IBS-D—none address the underlying microbial imbalance that growing evidence identifies as a central driver of IBS pathophysiology. This is precisely where probiotics enter the picture.
Why Probiotics for IBS? The Dysbiosis Link
A growing body of research confirms that the gut microbiome of IBS patients looks meaningfully different from that of healthy individuals. Studies using advanced sequencing technologies consistently document reduced microbial diversity, decreased stability in bacterial populations over time, and altered abundance of key genera—including reduced Lactobacillus species and dysregulated Bifidobacterium populations—in people with IBS.[2]
This dysbiosis matters for several interconnected reasons. Beneficial bacteria produce short-chain fatty acids (SCFAs) that nourish the intestinal lining and support epithelial barrier integrity. When microbial balance is disrupted, SCFA production declines, intestinal permeability increases, and inflammatory signaling can escalate—all of which have been linked to the visceral hypersensitivity and altered motility that characterize IBS.[8]
The Gut–Brain Axis and IBS
IBS is increasingly understood as a disorder of the gut–brain axis—the bidirectional communication network linking the enteric nervous system, the central nervous system, and the gut microbiome. Gut bacteria synthesize and modulate neurotransmitters including serotonin, GABA, and dopamine, and influence vagal nerve signaling that directly shapes pain perception, mood, and intestinal motility. In IBS patients, this axis is dysregulated: altered microbial populations produce different signaling metabolites, and the hypersensitive gut responds with amplified pain signals. Probiotics that restore bacterial balance may partially recalibrate this axis, which helps explain why studies often observe improvements not just in gut symptoms but also in quality of life and psychological wellbeing.[8]
The therapeutic logic of probiotics for IBS is therefore not simply "add good bacteria and hope for the best." It's mechanistically grounded: targeted probiotic strains can restore commensal bacterial populations, reinforce the intestinal barrier, modulate immune responses, and normalize gut motility signaling. A network meta-analysis of 72 randomized controlled trials confirmed that probiotics significantly outperformed placebo for global IBS symptom improvement (SMD −0.55, 95% CI −0.76 to −0.34), abdominal pain reduction, and quality of life enhancement.[9]
The key is strain selection. Not every probiotic delivers the same effect, and research has become increasingly sophisticated at identifying which strains benefit which IBS symptom profiles. Understanding the difference between single- and multi-strain probiotic formulas is a useful starting point—and the evidence for IBS heavily favors comprehensive formulations.
Best Probiotic Strains for IBS: What the Research Shows
The strains discussed below are drawn exclusively from MicroBiome Restore's formula. All have peer-reviewed clinical evidence relevant to IBS symptom management. The research picture is nuanced—no single strain works for every patient or every IBS subtype—but the strains below represent the best-supported options available in a multi-strain probiotic context.
Bacillus coagulans: The Best-Ranked Strain for Overall IBS Relief
Bacillus coagulans has emerged from the clinical literature as arguably the most comprehensively effective probiotic species for IBS. Its unique advantage is spore-forming biology: unlike fragile Lactobacillus and Bifidobacterium strains that can be damaged by stomach acid, B. coagulans survives gastrointestinal transit in dormant spore form and germinates in the intestine where it's needed.[10]
A network meta-analysis published in Frontiers in Cellular and Infection Microbiology, encompassing 43 RCTs and 5,531 IBS patients, found that B. coagulans ranked first among all probiotic species for IBS symptom relief rate, global symptom improvement, abdominal pain reduction, bloating, and straining scores.[3] A separate systematic review and meta-analysis confirmed that B. coagulans significantly improved IBS severity across multiple symptom domains including urgency, bowel habit satisfaction, straining, passage of gas, incomplete evacuation, and total symptom severity score (p < 0.00001).[10]
Individual RCTs reinforce these aggregate findings. A randomized, double-blind, placebo-controlled trial of B. coagulans GBI-30, 6086 found statistically significant improvements in abdominal pain and bloating across all seven weekly comparisons in the active group (p < 0.01).[11] A subsequent multicenter RCT of 100 participants using B. coagulans BCP92 over 12 weeks demonstrated significant improvement in IBS severity (p < 0.001), gastrointestinal symptom frequency (p < 0.001), stool consistency (p < 0.001), and mental stress relief (p = 0.001) compared to placebo.[12]
Lactobacillus plantarum: A Long-Standing IBS Standard
Lactobacillus plantarum has one of the longest clinical track records of any probiotic strain studied for IBS. Multiple randomized trials across different populations have examined its effects, with the majority showing meaningful symptom relief. You can read more about the full evidence base in our dedicated article on Lactobacillus plantarum health benefits.
A double-blind, placebo-controlled trial published in World Journal of Gastroenterology randomized 214 IBS patients meeting Rome III criteria to receive either L. plantarum 299v (DSM 9843) or placebo for four weeks. At week 4, both pain severity and pain frequency were significantly lower in the probiotic group versus placebo (p < 0.05). Bloating showed similar significant improvement. Notably, 78.1% of patients in the L. plantarum group rated the treatment's efficacy as "good or excellent" compared to just 8.1% in the placebo group (p < 0.01).[4]
In a separate network meta-analysis comparing probiotic species by IBS outcome, L. plantarum ranked second overall for symptom relief rate and first for quality of life improvement among IBS patients.[3] Earlier controlled studies of L. plantarum DSM 9843 also documented reductions in pain and flatulence at both the end of the four-week treatment and twelve months later at follow-up—an unusually durable result in the IBS literature.[13]
Lactobacillus acidophilus: Top-Ranked for Quality of Life and Pain
A network meta-analysis of 81 RCTs covering 9,253 IBS patients ranked Lactobacillus acidophilus DDS-1 first among individual probiotic strains for improving IBS Symptom Severity Scale scores (SUCRA 92.9%), and the species overall showed the lowest incidence of adverse events among all probiotic categories studied—a meaningful finding for long-term use.[14]
A PRISMA systematic review and multi-criteria decision analysis of 104 IBS clinical studies spanning 2011–2021 identified formulations based on L. rhamnosus and L. acidophilus as having the highest overall efficacy scores, particularly for quality of life, bloating, and abdominal pain.[5] The review noted L. acidophilus modifies the expression of pain-associated receptors (μ-opioid and cannabinoid receptors) in the GI tract—a potential mechanism behind its analgesic effects in IBS.[5] Learn more about the clinical evidence behind L. acidophilus dosage and clinical guidelines.
Lactobacillus rhamnosus: Barrier Repair and Symptom Reduction
Lactobacillus rhamnosus brings a mechanistically distinct contribution to IBS management: compelling evidence that it repairs the compromised intestinal barrier consistently documented in IBS patients. In a key study, pre-treatment with L. rhamnosus GG (LGG) prevented increased intestinal permeability induced by IBS-associated fecal supernatants in human intestinal enteroids, directly demonstrating barrier-protective effects relevant to IBS pathophysiology.[15]
The PRISMA multi-criteria analysis identified L. rhamnosus as the most abundantly studied strain in IBS clinical literature, typically appearing in combination with L. acidophilus and Bifidobacterium species—a composite that consistently achieved the highest efficacy scores among all formulations reviewed.[5] A separate narrative review documented a relative risk of clinical improvement of 7.69 for Lactobacillus species overall in IBS, with L. rhamnosus specifically linked to reduced abdominal pain intensity and frequency, and noted for strong intestinal adherence and production of antimicrobial peptides that compete effectively against pathogenic bacteria.[16] Explore the full evidence on L. rhamnosus benefits.
Lactobacillus gasseri: IBS Pain and Motility Support
Lactobacillus gasseri is perhaps the most underappreciated IBS-relevant strain in the clinical literature. A randomized, double-blind, placebo-controlled trial of L. gasseri BNR17 in diarrhea-predominant IBS patients showed significant improvement in diarrhea symptoms versus the control group, with significant QOL improvements across abdominal pain (p < 0.05), abdominal distension (p < 0.0001), satisfied defecation (p < 0.001), disruption of daily life (p < 0.05), days of troublesome IBS symptoms (p < 0.005), and mean defecation frequency (p < 0.01).[6]
A multicenter real-world study of 119 IBS patients supplemented with L. gasseri LA806 for four weeks found that 71.8% of patients experienced at least a 30% reduction in abdominal pain, with mean abdominal pain scores declining 54.2% (from 5.3 ± 2.2 to 2.2 ± 2.4, p < 0.0001). Pain improvements were statistically significant as early as week one, and the percentage of patients reporting severe IBS symptoms dropped from 42.4% to 4.2% by the end of supplementation—a tenfold decrease.[17] The broader evidence on L. gasseri dosage and clinical research is reviewed in our dedicated article.
Bifidobacterium infantis: Composite Benefit and Visceral Pain
Bifidobacterium infantis 35624 has an interesting clinical profile in IBS: the evidence for single-strain use is mixed, but its performance in composite multi-strain formulas is more consistently positive. A meta-analysis published in Current Medical Research and Opinion found that composite probiotics containing B. infantis significantly reduced abdominal pain (SMD 0.22; 95% CI 0.03–0.41) and bloating/distension (SMD 0.30; 95% CI 0.04–0.56) in IBS patients.[18]
Preclinical work has identified a compelling mechanism: B. infantis 35624 displays visceral anti-nociceptive (pain-blocking) effects, and a large multicenter clinical trial of 362 IBS patients found the strain at optimal dosage improved abdominal pain, composite IBS symptom scores, bloating, bowel dysfunction, incomplete evacuation, straining, and gas passage—with global symptom assessment exceeding placebo by more than 20% (p < 0.02).[19] Explore the evidence further in our article on B. infantis benefits and IBS clinical evidence.
All Six of These Strains. Plus 20 More.
MicroBiome Restore combines all the IBS-relevant strains discussed above—B. coagulans, L. plantarum, L. acidophilus, L. rhamnosus, L. gasseri, and B. infantis—with 20 additional evidence-backed strains, 7 certified organic prebiotics, and 80+ trace minerals. No fillers. No microcrystalline cellulose. No magnesium stearate. Just 15 billion CFU of clean, comprehensive probiotic support.
IBS Strain Comparison at a Glance
The table below summarizes the primary IBS-relevant evidence for each strain found in MicroBiome Restore covered in this article.
| Strain | Key IBS Evidence | Primary Symptom Benefit |
|---|---|---|
| Bacillus coagulans | Ranked #1 across 43 RCTs (5,531 patients); significant improvement across all major IBS symptom domains[3] | Global symptoms, pain, bloating, bowel habits |
| L. plantarum | 78.1% rated treatment "good/excellent" vs. 8.1% placebo in 214-patient RCT[4] | Abdominal pain, bloating, flatulence |
| L. acidophilus | Ranked #1 (SUCRA 92.9%) for IBS-SSS improvement across 81 RCTs[14] | Symptom severity, pain, lowest adverse events |
| L. rhamnosus | Highest efficacy scores in 104-study PRISMA meta-analysis; RR of clinical improvement 7.69[5] | Pain intensity, barrier repair, quality of life |
| L. gasseri | 71.8% achieved ≥30% pain reduction in multicenter study; 10x reduction in severe symptoms[17] | Abdominal pain, distension, bowel frequency |
| B. infantis | >20% global symptom improvement over placebo in 362-patient multicenter RCT[19] | Visceral pain, bloating, bowel satisfaction |
Why Multi-Strain Matters for IBS
One of the most consistent signals from the IBS probiotic literature is that multi-strain formulations outperform single-strain products—not as an absolute rule, but as a strong pattern across systematic reviews. A 2019 systematic review specifically found that "beneficial effects were more distinct in the trials using multi-strain supplements with an intervention of 8 weeks or more, suggesting that multi-strain probiotics supplemented over a period of time have the potential to improve IBS symptoms."[7]
The logic is straightforward when you consider that IBS dysbiosis involves multiple disrupted bacterial populations simultaneously. No single strain can restore microbial diversity, repair the barrier, modulate visceral sensitivity, and normalize motility all at once. A comprehensive multi-strain approach—with strains from different genera acting through complementary mechanisms—is more likely to address the full spectrum of what has gone wrong in the IBS gut.
Prebiotics and the IBS Equation
Probiotic strains need fuel to establish themselves in a disrupted gut environment. Prebiotics—non-digestible fibers that selectively feed beneficial bacteria—play a critical supporting role. MicroBiome Restore includes Jerusalem artichoke (a rich source of inulin, one of the most studied prebiotic fibers), Acacia senegal, and maitake mushroom as prebiotic ingredients—all of which selectively support Lactobacillus and Bifidobacterium populations, the two genera most relevant to IBS symptom management. The pullulan capsule itself adds prebiotic benefit, as pullulan is a fermentable polysaccharide. This synbiotic design—probiotics plus prebiotics together—is how comprehensive gut support is meant to work.
A related insight from the evidence: treatment duration matters. A three-level meta-analysis of 72 RCTs found that while shorter treatment durations (under 4 weeks) were associated with larger initial effect sizes, Bacillus-class probiotics maintained superiority on abdominal pain improvement across longer durations—suggesting that different strains have different kinetics of effect.[9] This aligns with the clinical recommendation to commit to probiotic supplementation for a minimum of four to eight weeks before evaluating response.
For context on how to evaluate what's actually in your probiotic and what to look out for, our guide on reading probiotic supplement labels for hidden fillers is a helpful resource. And if you're experiencing bloating specifically, we've covered the clinical strain evidence for that symptom in depth as well.
MicroBiome Restore: Built for the Full IBS Picture
MicroBiome Restore was formulated around the principle that every ingredient must earn its place. Its 26 strains span six bacterial genera—providing complementary mechanisms across barrier repair, SCFA production, immune modulation, motility support, and pathogen competition. At 15 billion CFU per serving, it meets the threshold clinical meta-analyses identify as effective (≥10⁹ CFU/day).[20] And its pullulan capsule offers a prebiotic-active, oxygen-resistant delivery system superior to standard HPMC alternatives.
What to Look for in a Probiotic for IBS
Choosing the right probiotic for IBS requires more than selecting a product with a high CFU count. Here are the criteria that matter based on the clinical evidence:
Strain Diversity and Genera Coverage
Look for formulas covering both Lactobacillus and Bifidobacterium species, with Bacillus strains if possible. The most impactful formulations in IBS research include representatives from multiple genera—not a single species repeated at high doses. The network meta-analysis comparing individual strains and mixtures found that mixtures consistently performed well across multiple IBS symptom domains simultaneously.[14]
Adequate CFU Count
A meta-analysis examining probiotic dosing in IBS found that 10⁹ CFU/day (1 billion) was the minimum effective threshold, with most successful trials using doses in the range of 10⁹ to 10¹⁰ CFU/day.[20] A formulation delivering 15 billion CFU across 26 strains provides meaningful per-strain coverage at levels consistent with trial dosing for the key species discussed above.
A Clean Formulation—Without Gut-Disruptive Fillers
This point may seem obvious, but many commercial probiotics contain ingredients that work against gut health. Microcrystalline cellulose (MCC) is the most common filler in probiotics and supplements broadly—yet emerging research raises legitimate questions about its interaction with the intestinal barrier. Magnesium stearate, used as a flow agent, has been shown to reduce the bioavailability of active ingredients. These are the last things you want in a formulation intended to repair gut health.
A truly filler-free probiotic uses capsule materials that contribute rather than detract—pullulan, for example, is fermented, provides a prebiotic effect, and forms a superior oxygen barrier that protects strain viability. Our article on HPMC vs. pullulan capsules for gut health explores this distinction in depth.
Commitment to Duration
Perhaps the most practical piece of advice from the clinical literature: give it time. Both the systematic reviews and individual RCTs demonstrate that probiotic effects in IBS are typically not immediate. Most studies showing significant results used intervention periods of four to twelve weeks. Starting a probiotic and discontinuing after two weeks because symptoms haven't resolved is the most common reason patients conclude probiotics "don't work" for them—when the evidence suggests longer supplementation is what allows the microbiome to genuinely shift.
A Note on Expectations
Probiotics are not a pharmaceutical cure for IBS, and the clinical evidence—while genuinely promising—is heterogeneous. Response rates vary by IBS subtype, individual microbiome baseline, and which strains are used. The evidence is strongest for global symptom improvement, abdominal pain reduction, and bloating relief; it is more mixed for specific bowel habit normalization. Probiotics work best as part of a comprehensive approach that may include dietary adjustments, stress management, and guidance from a gastroenterologist. If your IBS symptoms are severe or significantly disrupting your daily life, professional evaluation is always recommended before relying on supplementation alone.
Frequently Asked Questions
How long does it take for probiotics to help with IBS?
Most clinical trials showing significant IBS symptom improvement used 4–12 week intervention periods. Some patients notice changes within the first few weeks; others require longer. The network meta-analysis of 43 RCTs found that Bacillus-class probiotics showed superior abdominal pain improvement using 8-week protocols, while shorter durations produced initially larger but less durable effects across other strain types.[3] A minimum commitment of four to eight weeks is a reasonable expectation before evaluating whether a probiotic is working for your IBS.
Can probiotics make IBS symptoms worse?
Some people experience a transient increase in bloating or gas during the first one to two weeks of starting probiotics—this typically reflects the gut microbiome adjusting to the introduction of new bacterial populations. This is generally temporary and tends to resolve as supplementation continues. The network meta-analysis by Ouyang et al. found that L. acidophilus was associated with the lowest incidence of adverse events among all probiotic species studied for IBS.[14] If symptoms significantly worsen beyond mild initial adjustment, consider a lower starting dose and gradual titration upward, and consult your healthcare provider.
Do probiotics work for both IBS-C and IBS-D?
The short answer is yes, though different strains show different strengths by subtype. The majority of IBS probiotic trials include mixed populations covering IBS-C, IBS-D, and IBS-M, so much of the evidence applies broadly. That said, specific strains like L. gasseri have been more specifically studied in IBS-D, while L. rhamnosus IDCC 3201 has shown efficacy specifically in IBS-C.[21] We'll be covering probiotics for IBS-D and IBS-C in dedicated articles—for now, multi-strain formulas covering multiple mechanisms represent the most versatile approach across IBS subtypes.
Is 15 billion CFU enough for IBS?
Yes. A meta-analysis of 52 IBS probiotic trials found that probiotics began to show significant efficacy at doses of 10⁹ CFU/day (1 billion) or above, with a relative risk of overall symptom improvement of 1.64 and abdominal pain improvement of 1.69 at effective doses.[20] A multi-strain formula delivering 15 billion CFU across 26 strains distributes this dose meaningfully across multiple bacterial species, each contributing at therapeutically relevant levels. Higher CFU counts are not necessarily more effective than well-formulated, clinically relevant doses.
Should I take a probiotic with or without food if I have IBS?
The evidence here is nuanced—our comprehensive article on the best time to take probiotics covers this question in full. The short answer: for spore-forming Bacillus strains, timing relative to food matters less than for Lactobacillus and Bifidobacterium species. For the latter, taking probiotics with or just before a meal tends to buffer stomach acidity and improve strain survival to the intestine. Consistency of timing—the same time each day—matters more than perfection about the specific hour.
Can I take probiotics alongside IBS medication?
Generally yes, though certain scenarios warrant discussion with your physician. Probiotics are broadly safe for co-administration with standard IBS medications. However, if you are prescribed antibiotics for any reason, note that probiotics should typically be taken two hours apart from antibiotic doses to preserve bacterial viability, and you may want to continue or increase probiotic support post-antibiotic to restore gut balance—a topic covered in detail in our article on probiotics after antibiotics. If you are immunocompromised or have a serious underlying health condition, always consult your healthcare provider before starting any supplement.
Putting It All Together
The evidence base for probiotics in IBS has matured considerably over the past decade. What once looked like a collection of inconsistent small studies has developed into a body of systematic reviews and network meta-analyses involving thousands of patients—and the signal is clear: the right probiotic strains, in the right formulation, over an adequate duration, can meaningfully reduce abdominal pain, bloating, and the overall symptom burden of IBS.
Bacillus coagulans, Lactobacillus plantarum, L. acidophilus, L. rhamnosus, L. gasseri, and Bifidobacterium infantis represent the strongest single-strain evidence available—and MicroBiome Restore includes all of them, alongside 20 additional clinically studied strains, certified organic prebiotics including Jerusalem artichoke and acacia fiber, and a pullulan capsule that delivers them intact.
If you want to understand everything that goes into our formulation and why, the complete guide to MicroBiome Restore is the place to start. And if bloating is your primary concern, our dedicated article on evidence-based probiotics for bloating goes deeper on the strains most relevant to that specific symptom.
Your gut deserves a probiotic built on the same level of rigor as the science behind it.
Science-Backed. Filler-Free. Built for Gut Health.
MicroBiome Restore delivers the IBS-relevant strains covered in this article—plus 20 more evidence-backed strains, 7 certified organic prebiotics, and zero unnecessary fillers. Every ingredient earns its place in our formula.
References
- Canakis, A., Haroon, M., & Weber, H. C. (2023). Irritable bowel syndrome and the gut microbiome. World Journal of Gastroenterology, 24(5), 312–320. https://doi.org/10.1111/1751-2980.13204
- Shrestha, A., Bhatt, K., & Thapa, S. (2022). The role of gut-microbiota in the pathophysiology and therapy of irritable bowel syndrome: A systematic review. Cureus, 14(9), e29240. https://doi.org/10.7759/cureus.29240
- Liu, H., Wang, J., He, T., Bai, S., Yu, L., Shi, P., Zhang, D., Wang, Y., & Zhao, Y. (2022). Efficacy of probiotics for irritable bowel syndrome: A systematic review and network meta-analysis. Frontiers in Cellular and Infection Microbiology, 12, 859967. https://doi.org/10.3389/fcimb.2022.859967
- Ducrotté, P., Sawant, P., & Jayanthi, V. (2012). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World Journal of Gastroenterology, 18(30), 4012–4018. https://doi.org/10.3748/wjg.v18.i30.4012
- Pinto-Sanchez, M. I., & Bercik, P. (2022). Evaluating the efficacy of probiotics in IBS treatment using a systematic review of clinical trials and multi-criteria decision analysis. Nutrients, 14(13), 2689. https://doi.org/10.3390/nu14132689
- Shin, S. P., Choi, Y. M., Kim, W. H., Hong, S. P., Park, J. M., Kim, J., Kwon, O., Lee, E. H., & Hahm, K. B. (2018). A double blind, placebo-controlled, randomized clinical trial that breast milk derived Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. Journal of Clinical Biochemistry and Nutrition, 62(2), 179–186. https://doi.org/10.3164/jcbn.17-73
- Haavik-Nilsen, G., Aas, A. S., Thoresen, L., & Fadnes, L. T. (2019). Probiotics in irritable bowel syndrome: An up-to-date systematic review. Nutrients, 11(9), 2048. https://doi.org/10.3390/nu11092048
- Zhao, Y., & Zou, D. W. (2023). Gut microbiota and irritable bowel syndrome. Journal of Digestive Diseases, 24(5), 312–320. https://doi.org/10.1111/1751-2980.13204
- Zhao, Y., Dong, B. R., & Hao, Q. (2023). Probiotics for the management of irritable bowel syndrome: A systematic review and three-level meta-analysis. BMC Gastroenterology, 23(1), 360. https://pmc.ncbi.nlm.nih.gov/articles/PMC10651259/
- Madempudi, R. S., Ahire, J. J., Neelapu, N. R. R., & Bhatt, T. C. (2023). Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: A systematic review and meta-analysis of randomized control trials. International Journal of Surgery Open, 56, 100637. https://doi.org/10.1016/j.ijso.2023.100637
- Hun, L. (2009). Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgraduate Medicine, 121(2), 119–124. https://doi.org/10.3810/pgm.2009.03.1984
- Ghate, S. D., Ramesh, K., Rajendra, K., Jain, S., Arroyo-Johnson, C., & Mundkur, L. (2024). Role of Bacillus coagulans BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial. Medicine (Baltimore), 103(31), e39079. https://doi.org/10.1097/MD.0000000000039079
- Nobaek, S., Johansson, M. L., Molin, G., Ahrné, S., & Jeppsson, B. (2000). Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. American Journal of Gastroenterology, 95(5), 1231–1238. https://doi.org/10.1111/j.1572-0241.2000.02015.x
- Ouyang, Q., Hu, X., Tao, Y., Yin, F., & Chen, S. (2023). Outcome-specific efficacy of different probiotic strains and mixtures in irritable bowel syndrome: A systematic review and network meta-analysis. Nutrients, 15(19), 4198. https://doi.org/10.3390/nu15194198
- Han, X., Lee, A., Huang, S., Gao, J., Spence, J. R., & Owyang, C. (2019). Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes, 10(1), 59–76. https://doi.org/10.1080/19490976.2018.1479625
- Camilleri, M., & Boeckxstaens, G. (2018). A review of microbiota and irritable bowel syndrome: Future in therapies. Advances in Therapy, 35(3), 289–307. https://doi.org/10.1007/s12325-018-0673-5
- Merat, S., Rezailashkajani, M., Peyrovi, S., Ganji, A., Lankarani, K. B., Soltani, A., Malekzadeh, R., Sadeghi, R., & Sadeghi, R. (2022). Lactobacillus gasseri LA806 supplementation in patients with irritable bowel syndrome: A multicenter study. Journal of Clinical Medicine, 11(24), 7446. https://doi.org/10.3390/jcm11247446
- Yuan, F., Ni, H., Asche, C. V., Kim, M., Walayat, S., & Ren, J. (2017). Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: A meta-analysis. Current Medical Research and Opinion, 33(7), 1191–1197. https://doi.org/10.1080/03007995.2017.1292230
- Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. American Journal of Gastroenterology, 101(7), 1581–1590. https://doi.org/10.1111/j.1572-0241.2006.00544.x
- Zhang, T., Zhang, C., Zhang, J., Sun, F., & Duan, L. (2022). Efficacy of probiotics for irritable bowel syndrome: A systematic review and network meta-analysis. Frontiers in Cellular and Infection Microbiology, 12, 859967. https://doi.org/10.3389/fcimb.2022.859967
- Lee, H., Kim, M., Cho, C., & Kim, J. E. (2024). Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: A randomized, double-blind, and placebo-controlled trial. Scientific Reports, 14, 22395. https://doi.org/10.1038/s41598-024-72887-x
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!